Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant
Public ClinicalTrials.gov record NCT01666951. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Ph 2 Double-blind, Double-dummy, Multicenter, Prospective, Rand Study of PK of LCP-Tacro™ Tablets Once Daily, Compared to Prograf® Caps, Twice Daily, for Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the pharmacokinetics of LCP-Tacro tablets administered once-daily compared to Prograf capsules administered twice-daily after kidney transplantation.
Study identification
- NCT ID
- NCT01666951
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2012 (Type not available)
- Primary completion
- Mar 2013 (Actual)
- Completion
- May 2013 (Actual)
- Last update posted
- Jul 7, 2015
2012 – 2013
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Investigative Site 000015 | San Diego | California | 92123 | — |
| Clinical Investigative Site 000012 | San Francisco | California | 94115 | — |
| Clinical Investigative Site 00004 | Aurora | Colorado | 80045 | — |
| Clinical Investigative Site 000002 | Tampa | Florida | 33606 | — |
| Clinical Investigative Site 000005 | Lexington | Kentucky | 40536-0293 | — |
| Clinical Investigative Site 000009 | Ann Arbor | Michigan | 48109 | — |
| Clinical Investigative Site 000010 | Livingston | New Jersey | 07039 | — |
| Clinical Investigative Site 000011 | Buffalo | New York | 14215 | — |
| Clinical Investigative Site 00006 | New York | New York | 10016 | — |
| Clinical Investigative Site 00008 | Cleveland | Ohio | 44095 | — |
| Clinical Investigative Site 00003 | Philadelphia | Pennsylvania | 19104 | — |
| Clinical Investigative Site 000013 | Dallas | Texas | 75246 | — |
| Clinical Investigative Site 00001 | Charlottesville | Virginia | 22903 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01666951, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2015 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01666951 live on ClinicalTrials.gov.